Xeris Biopharma Holdings, Inc.

Historical 13F Holders

Symbol
XERS
CUSIP
98422E103
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 98422E103 since 12/18/2024, largest first.

Filer % of Class Filed
Vanguard Capital Management LLC 13G 5.0% 7/31/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (1)
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 13 1.34 M $12.9 M
2026 Q2 252 110 M $1.04 B
2026 Q1 247 105 M $611 M
2025 Q4 235 101 M $791 M
2025 Q3 237 97.8 M $796 M
2025 Q2 208 94.3 M $441 M
2025 Q1 208 87.6 M $481 M
2024 Q4 170 66.0 M $223 M
2024 Q3 149 64.3 M $183 M
2024 Q2 142 62.7 M $141 M
2024 Q1 150 63.8 M $141 M
2023 Q4 129 62.0 M $146 M
2023 Q3 119 55.7 M $104 M
2023 Q2 111 56.1 M $147 M
2023 Q1 96 49.5 M $80.6 M
2022 Q4 106 56.1 M $74.6 M
2022 Q3 111 57.3 M $89.4 M
2022 Q2 111 59.3 M $91.3 M
2022 Q1 112 50.7 M $130 M
2021 Q4 107 41.9 M $123 M
2021 Q3 1 704 k $1.73 M